Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 112,013

Document Document Title
WO/2016/124976A1
The invention relates to short RVG derived peptides for use in delivering therapeutic agents across the blood brain barrier and to target cells, for example those cells in the central nervous system. The invention provides method and com...  
WO/2016/124140A1
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (II) or pharmaceutically acce...  
WO/2016/126926A1
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections...  
WO/2016/127170A1
The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and...  
WO/2016/124564A1
The invention relates to n-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazi n-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sGC) for the treatment of cardiovascular diseases, such as for e...  
WO/2016/124125A1
The present invention relates to a new crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxa mide hydrochloride and a preparation method for the new crystalline form. The crystalline form has advantageous prope...  
WO/2016/124141A1
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (II) or pharmaceutically acce...  
WO/2016/127085A1
Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such ...  
WO/2016/124960A1
The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising ...  
WO/2016/123581A1
The present invention provides a malonate salt of a compound of formula (I), which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline...  
WO/2016/123627A1
Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for...  
WO/2016/123577A1
The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula (I), or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, in...  
WO/2016/123164A1
Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psyc...  
WO/2016/122832A1
Disclosed are compositions comprising Rg3 ginsenoside and nicotinamide riboside. These compositions are useful for treating and preventing diseases, conditions and disorders caused by microglia-mediated inflammation, including neurodegen...  
WO/2016/122968A1
The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3] thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.  
WO/2016/119701A1
The present invention relates to a novel type of PPARγ modulator having a pyrimido [5, 4-d]pyrimidine main structure. The PPARγ modulator can enhance the expression and nuclear translocation of PPARγ in cells. The present invention al...  
WO/2016/119700A1
Provided herein are substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms o...  
WO/2016/119031A1
The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of ...  
WO/2016/123533A1
Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure wherein R1, R2, R3 and n are as defined herein, inclu...  
WO/2016/123543A1
Disclosed herein are methods for treating schizophrenia in an individual. The invention further provides methods for determining if an individual suffering from schizophrenia is likely to respond favorably or experience an enhanced treat...  
WO/2016/121805A1
Provided is an adhesive patch capable of exhibiting exceptional tack on the skin when affixed thereto, said patch having a low incidence of detaching from the skin once affixed. This adhesive patch is characterized by including a support...  
WO/2016/122218A2
The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but ...  
WO/2016/119085A1
Disclosed is an application of ethyl p-methoxycinnamate and derivatives thereof in preparing drugs, culture media, regulating agents or cosmetics and skin care products for maintaining self-renewal and pluripotency of stem cells. The ste...  
WO/2016/118541A1
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  
WO/2016/117139A1
The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or bac...  
WO/2016/116768A1
The invention relates to diseases, disorders and conditions of the brain, and agents for treatment of the same.  
WO/2016/118741A1
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupu...  
WO/2016/116615A1
The present invention is concerned with an oral pharmaceutical dosage form comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain...  
WO/2016/116268A1
The present invention relates to the use of morphine-6-glucoronide as a medicine to neonates admitted to the neonatal intensive care unit.  
WO/2016/117416A1
The present invention provides a composition containing honey, bee pollen, royal jelly, and propolis, wherein the honey content is 70 mass% to less than 100 mass% of the total composition, the bee pollen is more than 0% and 10 mass% or l...  
WO/2016/117510A1
The present invention provides a method with which it is possible to directly induce nervous system cells efficiently and in a short amount of time. Because the method is easy to scale up and is not affected by the characteristics or bac...  
WO/2016/117647A1
Provided is a prophylactic or therapeutic drug for diseases involving Nav1.7, more specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain diso...  
WO/2016/118515A1
The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The s...  
WO/2016/116280A1
The invention relates to Cebranopadol or a physiologically acceptable salt thereof for use in the treatment or the prevention of pain and/or opioid drug dependence in a subject with impaired hepatic and/or renal function.  
WO/2016/118878A1
A supplement includes plant-derived phosphatidylserine in a physiologically beneficial amount and at least one plant-based concentrate or extract which promotes a melatonergic benefit.  
WO/2016/113549A1
The invention relates to 3α-ethynyl, 3β-hydroxy, 5α-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric ac...  
WO/2016/115054A2
Described herein are compounds that modulate the activity of CRAC channels, methods of making such compounds, pharmaceutical compositions, and medicaments containing such compounds, and methods of using such compounds in the treatment of...  
WO/2016/115057A1
Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor.  
WO/2016/112874A1
Disclosed are uses of 3,3',5,5'-tetraisopropyl-4,4'-diphenol, pharmaceutical salts thereof, esterification products thereof, or solvates thereof in the preparation of medicines for the prevention and treatment of cerebral ischemia.  
WO/2016/114602A1
Disclosed herein a pharmaceutical composition comprising aprepitant or a pharmaceutically acceptable salt thereof; at least one hydrocarbon derivative selected from among a fatty acid of 14 to 18 carbon atoms, and a fatty alcohol of 14 t...  
WO/2016/113635A1
The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non¬ alcoholic steatohepatitis (NASH) and their sequelae by administrat...  
WO/2016/115013A1
The present invention is directed to cinnoline derivatives of formula (I) pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the...  
WO/2016/114707A1
The present invention relates to derivatives of dehydroabietic acid useful in treatment ofcardiac arrhythmiaor a hyperexcitablity disease, such as epilepsy or pain, by extracellularly acting on the voltage sensitive domain (VSD) to open ...  
WO/2016/115290A1
The present invention provides polypeptides and their variants and derivatives which modulate GABAA receptor function at nanomolar quantities by binding to the α+/β- subunit interface, as well as methods of making and using the same. T...  
WO/2016/115223A1
This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition s...  
WO/2016/115382A1
The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering ...  
WO/2016/112875A2
The present invention relates to a diphenyl derivative and uses thereof, the diphenyl derivative having the structure as indicated in formula (I) defined in the description. The uses refer to the uses of the diphenyl derivative, pharmace...  
WO/2016/114386A1
A therapeutic agent for progressive demyelinating immune disease containing, as an active ingredient thereof, a substance for suppressing or inhibiting signal transduction initiated by the PAR1 receptor.  
WO/2016/114655A1
The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pha...  
WO/2016/113802A1
The present invention provides: a furoxan compound having a fluorine atom as a substituent group on the ring structure thereof; and a novel nitric oxide donor using said compound. The present invention is a fluorofuroxan compound represe...  

Matches 51 - 100 out of 112,013